Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034121120> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2034121120 endingPage "328" @default.
- W2034121120 startingPage "321" @default.
- W2034121120 abstract "Eribulin mesylate, a novel non-taxane microtubule dynamics inhibitor, is approved for treatment of metastatic breast cancer (MBC) in patients who have previously received at least 2 chemotherapeutic regimens for MBC that should have included an anthracycline and a taxane in the adjuvant or metastatic setting. This phase 2 study evaluated efficacy and safety of eribulin as first-line therapy for human epidermal growth factor receptor 2-negative (HER2-negative) MBC. Patients with measurable HER2-negative locally recurrent breast cancer or MBC with ≥12 months since prior neoadjuvant or adjuvant (neo/adjuvant) chemotherapy received eribulin mesylate 1.4 mg/m2 IV on days 1 and 8 of each 3-week cycle. Endpoints included objective response rate (ORR) per RECIST v1.1 (primary), safety, progression-free survival (PFS), clinical benefit rate (ORR + stable disease ≥6 months; CBR), and duration of response (DOR). Fifty-six patients were enrolled and received eribulin; 38 (68 %) had prior neo/adjuvant therapy, including 33 who had anthracycline and/or taxane-containing chemotherapy; 41 (73 %) had estrogen receptor-positive disease, and 12 (21 %) had estrogen receptor-negative, progesterone receptor-negative, and HER2-negative (triple-negative) disease. Patients received a median of 7 cycles (range 1–43); 6 (11 %) received treatment for ≥12 months. ORR was 29 % (95 % CI 17.3–42.2), CBR was 52 %, and median DOR was 5.8 months. Median PFS was 6.8 months. Thirty-six patients (64 %) had grade 3/4 treatment-related adverse events; most common were neutropenia (50 %), leukopenia (21 %), and peripheral neuropathy (21 %). These results demonstrate that eribulin has substantial antitumor activity as first-line treatment for HER2-negative MBC with acceptable safety." @default.
- W2034121120 created "2016-06-24" @default.
- W2034121120 creator A5032254106 @default.
- W2034121120 creator A5044957566 @default.
- W2034121120 creator A5052735457 @default.
- W2034121120 creator A5063914778 @default.
- W2034121120 creator A5071432873 @default.
- W2034121120 creator A5072563567 @default.
- W2034121120 creator A5078577803 @default.
- W2034121120 creator A5090864802 @default.
- W2034121120 date "2014-04-04" @default.
- W2034121120 modified "2023-09-24" @default.
- W2034121120 title "Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer" @default.
- W2034121120 cites W2018563247 @default.
- W2034121120 cites W2042941276 @default.
- W2034121120 cites W2074890479 @default.
- W2034121120 cites W2095832858 @default.
- W2034121120 cites W2096593771 @default.
- W2034121120 cites W2114826333 @default.
- W2034121120 cites W2123851255 @default.
- W2034121120 cites W2127152525 @default.
- W2034121120 cites W2132049943 @default.
- W2034121120 cites W2132445915 @default.
- W2034121120 cites W2154122152 @default.
- W2034121120 cites W2161426850 @default.
- W2034121120 cites W4241664300 @default.
- W2034121120 doi "https://doi.org/10.1007/s10549-014-2923-9" @default.
- W2034121120 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4643585" @default.
- W2034121120 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24699910" @default.
- W2034121120 hasPublicationYear "2014" @default.
- W2034121120 type Work @default.
- W2034121120 sameAs 2034121120 @default.
- W2034121120 citedByCount "43" @default.
- W2034121120 countsByYear W20341211202014 @default.
- W2034121120 countsByYear W20341211202015 @default.
- W2034121120 countsByYear W20341211202016 @default.
- W2034121120 countsByYear W20341211202017 @default.
- W2034121120 countsByYear W20341211202018 @default.
- W2034121120 countsByYear W20341211202019 @default.
- W2034121120 countsByYear W20341211202020 @default.
- W2034121120 countsByYear W20341211202021 @default.
- W2034121120 countsByYear W20341211202022 @default.
- W2034121120 countsByYear W20341211202023 @default.
- W2034121120 crossrefType "journal-article" @default.
- W2034121120 hasAuthorship W2034121120A5032254106 @default.
- W2034121120 hasAuthorship W2034121120A5044957566 @default.
- W2034121120 hasAuthorship W2034121120A5052735457 @default.
- W2034121120 hasAuthorship W2034121120A5063914778 @default.
- W2034121120 hasAuthorship W2034121120A5071432873 @default.
- W2034121120 hasAuthorship W2034121120A5072563567 @default.
- W2034121120 hasAuthorship W2034121120A5078577803 @default.
- W2034121120 hasAuthorship W2034121120A5090864802 @default.
- W2034121120 hasBestOaLocation W20341211201 @default.
- W2034121120 hasConcept C121608353 @default.
- W2034121120 hasConcept C126322002 @default.
- W2034121120 hasConcept C143998085 @default.
- W2034121120 hasConcept C2775930923 @default.
- W2034121120 hasConcept C2776387010 @default.
- W2034121120 hasConcept C2776802502 @default.
- W2034121120 hasConcept C2777511904 @default.
- W2034121120 hasConcept C530470458 @default.
- W2034121120 hasConcept C71924100 @default.
- W2034121120 hasConcept C90924648 @default.
- W2034121120 hasConceptScore W2034121120C121608353 @default.
- W2034121120 hasConceptScore W2034121120C126322002 @default.
- W2034121120 hasConceptScore W2034121120C143998085 @default.
- W2034121120 hasConceptScore W2034121120C2775930923 @default.
- W2034121120 hasConceptScore W2034121120C2776387010 @default.
- W2034121120 hasConceptScore W2034121120C2776802502 @default.
- W2034121120 hasConceptScore W2034121120C2777511904 @default.
- W2034121120 hasConceptScore W2034121120C530470458 @default.
- W2034121120 hasConceptScore W2034121120C71924100 @default.
- W2034121120 hasConceptScore W2034121120C90924648 @default.
- W2034121120 hasIssue "2" @default.
- W2034121120 hasLocation W20341211201 @default.
- W2034121120 hasLocation W20341211202 @default.
- W2034121120 hasLocation W20341211203 @default.
- W2034121120 hasLocation W20341211204 @default.
- W2034121120 hasOpenAccess W2034121120 @default.
- W2034121120 hasPrimaryLocation W20341211201 @default.
- W2034121120 hasRelatedWork W1937628254 @default.
- W2034121120 hasRelatedWork W2325136564 @default.
- W2034121120 hasRelatedWork W2327550265 @default.
- W2034121120 hasRelatedWork W2526703400 @default.
- W2034121120 hasRelatedWork W2612052752 @default.
- W2034121120 hasRelatedWork W3092350130 @default.
- W2034121120 hasRelatedWork W4205779066 @default.
- W2034121120 hasRelatedWork W4245186715 @default.
- W2034121120 hasRelatedWork W4248999504 @default.
- W2034121120 hasRelatedWork W4250466167 @default.
- W2034121120 hasVolume "146" @default.
- W2034121120 isParatext "false" @default.
- W2034121120 isRetracted "false" @default.
- W2034121120 magId "2034121120" @default.
- W2034121120 workType "article" @default.